Anavex Life Sciences (AVXL) Assets Average (2012 - 2025)
Anavex Life Sciences (AVXL) posted Assets Average of $118.4 million for Q4 2025, up 14.82% sequentially from $103.1 million in Q3 2025, and down 8.78% YoY from $129.8 million in Q4 2024.
Anavex Life Sciences (AVXL) Assets Average (2012 - 2025) Analysis & Trends
Anavex Life Sciences has reported Assets Average for 13 years, with the latest figure at $118.4 million in Q4 2025.
- Quarterly Assets Average fell 8.78% year-over-year to $118.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $118.4 million (down 8.78% YoY) and the FY2025 annual result came in at $119.7 million, down 17.44% from the prior year.
- Assets Average advanced to $118.4 million in Q4 2025 per AVXL's latest filing, from $103.1 million in the prior quarter.
- Over five years, Assets Average peaked at $164.0 million in Q3 2021 and troughed at $69.0 million in Q1 2021.
- A 5-year average of $138.6 million and a median of $148.4 million in 2022 frame the typical range for Assets Average.
- The sharpest annual moves came in 2021 and 2025: Assets Average jumped 395.73% in 2021, then declined 25.57% in 2025.
- Over 5 years, Assets Average stood at $159.3 million in 2021, then fell by 5.47% to $150.5 million in 2022, then grew by 0.46% to $151.2 million in 2023, then retreated by 14.17% to $129.8 million in 2024, then dropped by 8.78% to $118.4 million in 2025.
- According to Business Quant data, Assets Average over the past three periods registered $118.4 million, $103.1 million, and $109.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Anavex Life Sciences | 298.40 Mn | 166.65 Mn | - | 118.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 118.40 Mn |
| Sep 30, 2025 | 103.12 Mn |
| Jun 30, 2025 | 109.79 Mn |
| Mar 31, 2025 | 120.59 Mn |
| Dec 31, 2024 | 129.81 Mn |
| Sep 30, 2024 | 138.55 Mn |
| Jun 30, 2024 | 143.03 Mn |
| Mar 31, 2024 | 146.29 Mn |
| Dec 31, 2023 | 151.23 Mn |
| Sep 30, 2023 | 156.10 Mn |
| Jun 30, 2023 | 158.50 Mn |
| Mar 31, 2023 | 153.78 Mn |
| Dec 31, 2022 | 150.54 Mn |
| Sep 30, 2022 | 156.46 Mn |
| Jun 30, 2022 | 160.25 Mn |
| Mar 31, 2022 | 158.59 Mn |
| Dec 31, 2021 | 159.26 Mn |
| Sep 30, 2021 | 164.02 Mn |
| Jun 30, 2021 | 125.00 Mn |
| Mar 31, 2021 | 68.95 Mn |